0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

β-Blockers and Sudden Cardiac Death

Martin J. Kendall, MD, FRCP; Kevin P. Lynch, MBBS; Ake Hjalmarson, MD, PhD; and John Kjekshus, MD, PhD
[+] Article and Author Information

From Queen Elizabeth Hospital, Birmingham, United Kingdom; Sahlgren's Hospital, Gothenburg, Sweden; and The National Hospital and the University of Oslo, Oslo, Norway. Grant Support: In part by an educational grant from Astra Hassle, Molndal, Sweden. Requests for Reprints: Martin J. Kendall, Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Birmingham M15 2TH, United Kingdom. Current Author Addresses: Drs. Kendall and Lynch: Clinical Pharmacology Section, Department of Medicine, Queen Elizabeth Hospital, Birmingham M15 2TH, United Kingdom.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1995;123(5):358-367. doi:10.7326/0003-4819-123-5-199509010-00007
Text Size: A A A

Objectives: To 1) consider the problem of sudden death from heart disease and the role of β-blockers and other agents in preventing sudden death and 2) review perceived problems with β-blocker therapy, such as effects on blood lipids, complications in diabetes, and adverse effects on heart failure and quality of life.

Data Sources: MEDLINE and EMBASE searches done from July 1994 on, and recognized texts.

Study Selection: More than 400 original and review articles were evaluated, of which the most relevant were selected.

Data Extraction: Data were extracted and reviewed by two authors. Accuracy was confirmed, when necessary, by the other authors.

Data Synthesis: Of all of the therapies currently available for the prevention of sudden cardiac death, none is more established or more effective than β-blockers. Indeed, the evidence that β-blockers have a cardioprotective effect is compelling. They probably reduce the rate of atheroma formation; they reduce the risk for ventricular fibrillation in animal models of myocardial ischemia; they appear to reduce cardiac mortality in primary prevention trials; and they reduce mortality, particularly from sudden death, in patients who have had infarction. Moreover, withholding β-blockers because of problems perceived to be associated with them is usually not warranted and may frequently prevent their use in those who will benefit most from them.

Conclusion: Clinicians should reappraise the evidence for the significant effect of β-blockers on morbidity and mortality, and they should recognize the importance of initiating and maintaining β-blocker therapy when the less well-informed might suggest other-wise.

Figures

Grahic Jump Location
Figure 1.
Sudden cardiovascular deaths in hypertensive patients.[17]

Reproduced with permission from American Journal of Hypertension .

Grahic Jump Location
Grahic Jump Location
Figure 2.
Cumulative number of sudden deaths reported in five postinfarction trials.[30]

Reproduced with permission from the European Heart Journal .

Grahic Jump Location
Grahic Jump Location
Figure 3.
Effect of β-blocker therapy on mortality and reinfarction rates in patients with and without diabetes after myocardial infarction, expressed as percentage reduction compared with patients receiving placebo.

Adapted from data in references 90 and 91.

Grahic Jump Location
Grahic Jump Location
Figure 4.
Cumulative history (Hx) of congestive heart failure (CHF) by previous history of CHF and by treatment group.[98]

Adapted with permission from Circulation .

Grahic Jump Location
Grahic Jump Location
Figure 5.
Effect of propranolol on morbidity and mortality related to the presence or absence of congestive heart failure (CHF).[98]

Adapted with permission from Circulation .

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)